Zhang L, Lin H, Wu W, Zhuang J, Huang L, Wang Y, Liu J, Hu C, Wei X (2024) A meta-analysis of the impact of pharmacist interventions on clinical outcomes in patients with type-2 diabetes
Results announced in December 2025 confirmed the Phase 2 findings at a longer timepoint (Lilly Press Release, Dec 2025): The 28.7% weight loss at 68 weeks exceeds both semaglutide (~15% in STEP trials) and tirzepatide (~22.5% in SURMOUNT trials) at similar timepoints
Clinical trials show a 12.4% average weight loss among participants
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
How to Identify High-Quality Retatrutide Not all suppliers maintain the same quality standards
In ADP-ribosylation factor 2-interacting protein (Arfip2)-knockout human podocytes and Arfip2 knockout and streptozotocin (STZ)-induced mouse models, Arfip2 deficiency worsens autophagy in diabetic mice and leads to loss of pedicle protrusions, histopathological alterations, and early albuminuria, and in human podocytes, Arfip2 deficiency interferes with autophagy-associated protein 9a (ATG9A) transport and the PINK1/Parkin pathway, resulting in impaired mitochondrial fission and reduced mitophagy, thus Arfip2 may be a novel factor regulating autophagy and mitochondrial homeostasis in foot cells [111]
